Olema reports Q1 net loss $53.1M, cash $505.3M; Phase 3 OPERA-01 data due fall 2026

Olema Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.52 vs consensus -$0.54 ▲ beat (+3.6%)

Cash, equivalents, and marketable securities $505.3M as of March 31, 2026.
Net loss Q1 2026: $53.1M vs $30.4M Q1 2025, driven by higher R&D spend.
GAAP R&D expenses $49.2M (Q1 2026) vs $30.6M (Q1 2025); non-GAAP R&D $42.7M.
Top-line data from pivotal Phase 3 OPERA-01 (palazestrant monotherapy) expected fall 2026.
Initial Phase 1 data for OP-3136 to be presented at ASCO 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Olema Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026 was $53.1 million, as compared to $30.4 million for the quarter ended Marc.

Period: the quarter ended March 31, 2026
Net income: Net loss for the quarter ended March 31, 2026 was $53.1 million, as compared to $30.4 million for the quarter ended Marc
Result: reported results

Exact text from the filing

On May 12, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended March 31, 2026.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Olema Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-218142

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.